Paul S. Jellinger, MD

Feature

Initiating Injectable Treatment of Type 2 Diabetes: A Focus on Glucagon-Like Peptide-1 Receptor Agonists

05/02/2017

This review examines the literature on injectable glucagon-like peptide-1 receptor agonists and their potential benefits.

05/02/2017

Research Summaries

Case in Point

Case in Point

Communication Barriers Concerning Implantable Cardioverter Defibrillator Deactivation Near End of Life

12/13/2024

W. Clay Jackson, MD, DipTh

A 62-year-old woman presented to a palliative care clinic for follow-up of symptom management. She reported a recent fall after unexpectedly being shocked by her implantable cardioverter-defibrillator...

12/13/2024

Roundtable

Roundtable

Initiating Resmetirom for Patients With MASH: Recommendations on Patient Selection, Treatment Response, and Patient Monitoring

12/12/2024

Naim Alkhouri, MD; Amreen M. Dinani, MD, FRCPC; Mazen Noureddin, MD, MHSc

In this video, Naim Alkhouri MD, FAASLD moderates a roundtable discussion with Amreen M. Dinani, MD, FRCPC and Mazen Noureddin, MD, MHSc on the practical clinical applications associated with starting and...

12/12/2024

Pop Quiz

X-ray of man's liver, as he clutches it in pain.

Pop Quiz

Hepatocellular Carcinoma Risk in Acute Hepatic Porphyria

12/11/2024

A recent meta-analysis examines the incidence of hepatocellular carcinoma in patients with acute hepatic porphyria, identifying higher risks in certain subgroups. Test your knowledge of these findings with...

12/11/2024

Agitation in Alzheimer Disease

Agitation in Alzheimer Disease

Dronabinol Reduces Agitation in Patients With Alzheimer Disease

12/11/2024

Anthony Calabro, MA

In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...

12/11/2024

Research Summary

Semaglutide Reduces Abdominal VAT in Patients With HIV-Related Lipohypertrophy

12/11/2024

Miranda Manier, BA

A clinical trial suggests semaglutide significantly reduces abdominal fat in HIV-associated lipohypertrophy, but the potential for adverse events warrant further investigation.

12/11/2024

November 2024

Current Issue

November 2024